There are plenty of reasons, though, to be bullish on the stock, not the least of which is its improved cash position. The ...

Wondering if CRISPR Therapeutics at around US$51.22 is pricing in too much hope or leaving room on the table? This article walks through what the current share price may be implying about the company.

Results from two years of field trials demonstrate that wheat produced using CRISPR genome editing can significantly lower ...

Over the past five years, CRISPR Therapeutics (CRSP) has significantly underperformed the broader market. There are multiple ...

According to TipRanks.com, Lutz is a 5-star analyst with an average return of 11.8% and a 63.1% success rate. Lutz covers the Healthcare sector, focusing on stocks such as Hims & Hers Health, Envista ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

With an approved treatment in commercial stages and new drug candidates generating clinical trial results, this biotech has ...

Learn more about whether Relay Therapeutics, Inc. or Twist Bioscience Corporation is a better investment based on AAII's A+ ...

Context for CRISPR Therapeutics stock CRISPR Therapeutics (CRSP) trades around US$49.51, with recent returns ranging from a 1 day gain of about 1.4% to a past month decline of roughly 13.6% and a past ...

Find the latest Stock Market news from WIRED. See related science and technology articles, photos, slideshows and videos.

What if the biggest winners in biotech weren’t the ones promising miracle cures, but the ones quietly supplying the picks and ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.